Tamara Miller

1.9k total citations · 1 hit paper
23 papers, 958 citations indexed

About

Tamara Miller is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Tamara Miller has authored 23 papers receiving a total of 958 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 6 papers in Neurology and 6 papers in Oncology. Recurrent topics in Tamara Miller's work include Multiple Sclerosis Research Studies (16 papers), Peripheral Neuropathies and Disorders (5 papers) and Polyomavirus and related diseases (5 papers). Tamara Miller is often cited by papers focused on Multiple Sclerosis Research Studies (16 papers), Peripheral Neuropathies and Disorders (5 papers) and Polyomavirus and related diseases (5 papers). Tamara Miller collaborates with scholars based in United States, Canada and Czechia. Tamara Miller's co-authors include Eva Havrdová, Stephen Lake, Edward Fox, Cary Twyman, Howard L. Weiner, Alasdair Coles, Michael Panzara, Christian Confavreux, Krzysztof Selmaj and Jeffrey Cohen and has published in prestigious journals such as The Lancet, The Journal of Clinical Endocrinology & Metabolism and Neurology.

In The Last Decade

Tamara Miller

21 papers receiving 935 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

2012 884 citations Alasdair Coles, Cary Twyman et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tamara Miller United States	6	799	319	288	247	244	23	958
Bella Ertik United States	5	756 0.9×	286 0.9×	272 0.9×	236 1.0×	248 1.0×	7	930
M. Stojanovic Serbia	8	815 1.0×	361 1.1×	271 0.9×	249 1.0×	241 1.0×	18	1.0k
Pedro Oyuela United States	7	938 1.2×	362 1.1×	368 1.3×	286 1.2×	326 1.3×	16	1.2k
Karthinathan Thangavelu United States	14	585 0.7×	226 0.7×	240 0.8×	206 0.8×	161 0.7×	58	779
Pierangelo Barbero Italy	15	623 0.8×	408 1.3×	259 0.9×	289 1.2×	134 0.5×	34	951
T. Pickersgill United Kingdom	8	582 0.7×	253 0.8×	141 0.5×	192 0.8×	193 0.8×	12	730
Ernesto Roldán Spain	15	451 0.6×	224 0.7×	194 0.7×	143 0.6×	416 1.7×	26	884
Lisa Costelloe Ireland	11	483 0.6×	134 0.4×	191 0.7×	137 0.6×	485 2.0×	15	1.0k
Timon Bogumil Germany	12	561 0.7×	216 0.7×	186 0.6×	230 0.9×	181 0.7×	21	1.2k
Florence Casset‐Semanaz Switzerland	8	423 0.5×	193 0.6×	157 0.5×	165 0.7×	114 0.5×	11	566

Countries citing papers authored by Tamara Miller

Since Specialization

Citations

This map shows the geographic impact of Tamara Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamara Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamara Miller more than expected).

Fields of papers citing papers by Tamara Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamara Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamara Miller. The network helps show where Tamara Miller may publish in the future.

Co-authorship network of co-authors of Tamara Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Tamara Miller. A scholar is included among the top collaborators of Tamara Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamara Miller. Tamara Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Witchel, Selma F., et al.. (2025). Life With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: Challenges and Burdens. The Journal of Clinical Endocrinology & Metabolism. 110(Supplement_1). S56–S66.

Wray, Sibyl, François Jacques, Tamara Miller, et al.. (2022). Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study. Multiple Sclerosis Journal - Experimental Translational and Clinical. 8(4). 3090499088–3090499088. 6 indexed citations

Kaplan, Jeffrey, et al.. (2020). A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse. Frontiers in Neurology. 11. 598496–598496. 8 indexed citations

Tran, Vincent, et al.. (2019). The Effect of Ocrelizumab Therapy on Immunoglobulin Levels in Patients with Multiple Sclerosis (P4.2-042). Neurology. 92(15_supplement). 2 indexed citations

Wray, Sibyl, François Jacques, Tamara Miller, et al.. (2019). Treatment Sequencing and Satisfaction With Alemtuzumab in Relapsing Multiple Sclerosis Patients: Interim Results of the Real-world PRO-ACT Study (P3.2-097). Neurology. 92(15_supplement). 1 indexed citations

Chinea, Ángel, William Honeycutt, Tamara Miller, et al.. (2019). Effect of Alemtuzumab Infusions on Vital Signs. International Journal of MS Care. 22(2). 53–59. 6 indexed citations

Miller, Paul, et al.. (2019). Adrenal Insufficiency and Multiorgan Failure in a Patient Receiving Alemtuzumab Therapy (P5.2-074). Neurology. 92(15_supplement).

Hartung, Hans, Timothy Vollmer, Douglas L. Arnold, et al.. (2013). Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07.093). Neurology. 80(7_supplement). 2 indexed citations

Sørensen, Per Soelberg, Douglas L. Arnold, Jeffrey A. Cohen, et al.. (2013). Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101). Neurology. 80(7_supplement). 4 indexed citations

10.

Giovannoni, Gavin, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120). Neurology. 80(7_supplement). 1 indexed citations

11.

Wray, Sibyl, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Comparison of Infection Risk with Alemtuzumab and SC IFNB-1a in Patients with Multiple Sclerosis Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.172). Neurology. 80(7_supplement). 1 indexed citations

12.

LaGanke, Christopher, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174). Neurology. 80(7_supplement). 3 indexed citations

13.

Miller, Tamara, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Detection, Incidence, and Management of Thyroid Autoimmunity in Comparison of Alemtuzumab and Rebif® in Multiple Sclerosis (CARE-MS) I and II (P01.173). Neurology. 80(7_supplement). 1 indexed citations

14.

Twyman, Cary, Xavier Montalbán, Douglas L. Arnold, et al.. (2013). Relapse Outcomes with Alemtuzumab vs IFNB-1a in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.098). Neurology. 80(7_supplement). 1 indexed citations

15.

Freedman, Mark S., Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Efficacy of Alemtuzumab vs IFNB-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II): Subgroup Analysis by Previous Disease Modifying Therapy (DMT) Use (P07.111). Neurology. 80(7_supplement). 2 indexed citations

16.

Coles, Alasdair, Cary Twyman, Douglas L. Arnold, et al.. (2012). Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet. 380(9856). 1829–1839. 884 indexed citations breakdown →

17.

Singer, B., Sibyl Wray, Tamara Miller, et al.. (2012). Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 1(2). 87–94. 14 indexed citations

18.

Bandari, Daniel S., Daniel Wynn, Tamara Miller, et al.. (2012). Rebif® Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis. Multiple Sclerosis and Related Disorders. 2(1). 45–56. 5 indexed citations

19.

Cohen, Jeffrey, Cary Twyman, Douglas L. Arnold, et al.. (2012). Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy (S01.004). Neurology. 78(Meeting Abstracts 1). S01.004–S01.004. 5 indexed citations

20.

Hogan, Patrick, et al.. (2004). Severity and impact of xerostomia in patients treated with botulinum toxin type b for cervical dystonia: Observations on the quality of life of patients with xerostomia. Current Therapeutic Research. 65(2). 161–171. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact